Fuji Photo Film invests in U.S. bio-venture companies and joins the Cosmos Alliance

May 24, 2005


Fuji Photo Film Co., Ltd. (President and CEO: Shigetaka Komori; hereinafter referred to as "Fujifilm") has joined the Cosmos Alliance (HQ: Washington DC, USA; CEO and Chairman: Dr. Frank Young), an international membership organization established to encourage technology exchange for promotion of the commercialization of leading-edge technologies in the bio life-science field. At the same time, Fujifilm has invested $500,000 each in two U.S. venture companies, Agennix Incorporated and Panacea Pharmaceuticals, Inc., both of which are members of the Cosmos Alliance.

Fujifilm established its Life Science Division on April 1, 2005. In conjunction with its R&D establishment, including the Life Science Research Laboratories established in January 2004 and the Advanced Core Technology Laboratories, Fujifilm has now established a new structure for developing the life-science field as one of its core businesses. In addition to the research, development, and commercialization of its in-house technologies based on the new structure, Fujifilm has joined the Cosmos Alliance to strengthen its ties with U.S. venture companies and organizations possessing leading-edge technologies in the bio life-science field, and to start new businesses through collaborations in R&D. In addition to the two companies already invested in, Fujifilm is considering investing in three additional companies, and intends to promote alliance activities.

Overview of the Cosmos Alliance (http://www.cosmosalliance.com)
Headquarters: Washington D.C., U.S.; established in 2002
The Cosmos Alliance was established at the urging of Dr. Frank Young, ex-Commissioner of the US Food and Drug Administration. The Cosmos Alliance has strong connections with universities and research institutions, and contributes to research, development, and commercialization of new technologies by supporting international alliances between bio life-science venture companies with leading-edge technologies and well-established companies with technological prowess and capital strength.

Overview of Agennix Incorporated (http://www.agennix.com)
Headquarters: Houston, Texas, U.S.; established in 1993
Based on technologies developed at Baylor College of Medicine in the U.S., Agennix Incorporated seeks treatments for cancer, asthma, surgical wounds, and other such conditions through the use of rhLF (recombinant human lactoferrin). Lactoferrin is an immunomodulatory protein found abundantly in human milk (particularly in colostrum). Agennix Incorporated possesses the world's only human lactoferrin production technology on a commercial scale.

Overview of Panacea Pharmaceuticals, Inc. (http://www.panaceapharma.com)
Headquarters: Gaithersburg, Maryland, U.S.; established in 1999
Panacea Pharmaceuticals, Inc. holds the basic patent for HAAH (aspartyl beta-hydroxylase), an enzyme protein used as a cancer marker developed at Brown University in the U.S., and engages in collaborative research and out-licensing business with well-established companies.



Media contact:
Fuji Photo Film Co. Ltd.
Corporate Communications Division, Public Relations Division
TEL: 81-3-3406-2490
Customer contact:
Life Science Division
TEL: 81-3-3406-2201
Fujifilm website:
Japanese: http://www.fujifilm.co.jp/
English: http://www.fujifilm.com/